- Scinai Immunotherapeutics Ltd. has acquired 100% of Recipharm Israel Ltd., adding a cGMP API manufacturing site in Yavne, Israel, to its CDMO platform.
- The company also entered into a long-term commercial collaboration with Recipharm to create an integrated early-to-commercial development and contract manufacturing pathway.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has acquired 100% of the shares of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, and simultaneously entered into a long-term strategic commercial collaboration with Recipharm. The transactions expand Scinai’s manufacturing footprint and strengthen its CDMO and contract manufacturing platform by linking early-stage development with late-stage clinical and commercial supply capabilities.
Under the Share Purchase Agreement, Scinai acquired Recipharm Israel Ltd., preserving operational continuity, including employees, quality systems, regulatory approvals, customer contracts, and ongoing operations. The Yavne site provides early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (APIs) for clinical programs. Following closing, the site will operate as part of Scinai’s CDMO platform, complementing its existing Jerusalem-based capabilities in early-stage development, analytics, and clinical manufacturing. Financial terms were not disclosed.
In parallel, Scinai and Recipharm signed a Commercial Collaboration Agreement covering the full development lifecycle. Scinai will act as a preferred partner for early-stage development and clinical manufacturing within the Recipharm ecosystem, while Recipharm will serve as one of Scinai’s preferred partners for late-stage clinical and commercial manufacturing. The framework includes predefined commercial terms, mutual project referrals, and shared economics as programs transition between development stages.
The collaboration also establishes a Master Quality Agreement and a Tech Transfer Framework Agreement to align quality systems, regulatory compliance, and program transfers. According to Scinai, the structure is designed to reduce friction and delay when client programs move from early-stage development to global late-stage or commercial manufacturing, creating a more integrated pathway from development through commercialization.
“This transaction fundamentally strengthens Scinai’s CDMO platform. By combining our early-stage development strengths with Recipharm Israel’s manufacturing capabilities and Recipharm’s global footprint, we are creating a differentiated offering that supports clients from early development through commercialization.”
Amir Reichman, Chief Executive Officer of Scinai
